SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.
Treatment of Mycobacterium avium disease remains challenging when macrolide resistance develops. We infected C57 beige mice and treated them with mefloquine, SRI-286, and moxifloxacin. SRI-286 (80 mg/kg) was bactericidal in the liver. Mefloquine plus moxifloxacin or mefloquine plus SRI-286 were better than mefloquine alone.
Kuzell Institute, California Pacific Medical Center Research Institute, San Francisco, California, USA. uiz.bermudez@oregonstate.edu
Luiz E
LE
Bermudez
Peter
P
Kolonoski
Lianne E
LE
Seitz
Mary
M
Petrofsky
Robert
R
Reynolds
Martin
M
Wu
Lowell S
LS
Young
D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001372:Aza Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones; D008099:Liver / Q000382:microbiology; D015767:Mefloquine / Q000009:adverse effects / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D000077266:Moxifloxacin; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy* / Q000382:microbiology; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use*; D013154:Spleen / Q000382:microbiology; D013828:Thioacetazone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; C477303:SRI 286; D013828:Thioacetazone; D015767:Mefloquine; D000077266:Moxifloxacin